Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
1.030
+0.055 (5.61%)
At close: Dec 24, 2024, 4:00 PM
1.020
-0.010 (-0.97%)
After-hours: Dec 24, 2024, 4:15 PM EST
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2023. The number of employees decreased by 11 or -18.33% compared to the previous year.
Employees
49
Change (1Y)
-11
Growth (1Y)
-18.33%
Revenue / Employee
$213,878
Profits / Employee
-$770,245
Market Cap
12.15M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
STRATA Skin Sciences | 99 |
Lyra Therapeutics | 88 |
Apollomics | 45 |
Imunon | 33 |
Brainstorm Cell Therapeutics | 29 |
AIM ImmunoTech | 28 |
Sensei Biotherapeutics | 28 |
Eterna Therapeutics | 8 |
JAGX News
- 6 days ago - Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - Accesswire
- 7 days ago - Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder - Accesswire
- 8 days ago - FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera - Accesswire
- 12 days ago - Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer - Accesswire
- 13 days ago - Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - Accesswire
- 16 days ago - Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) - Accesswire
- 19 days ago - U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins - Accesswire
- 20 days ago - Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine - Accesswire